Inovio Pharmaceuticals (INO) Total Debt (2010 - 2026)

Inovio Pharmaceuticals has disclosed Total Debt across 17 years of filings, most recently posting $25.0 million for Q2 2026.

• In Q2 2026, Total Debt rose 119.13% year-over-year to $25.0 million; the TTM figure through Jun 2026 stood at $25.0 million (up 119.13% YoY), while the FY2025 annual figure was $29.1 million, up 119.29% from the prior year.
• Total Debt came in at $25.0 million for Q2 2026 at Inovio Pharmaceuticals, roughly flat from $24.9 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $50.4 million in Q3 2025 to a low of $1.2 million in Q4 2022.
• Average Total Debt over 5 years is $15.8 million, with a median of $16.5 million recorded in 2023.
• Year-over-year, Total Debt slipped 24.53% in 2022 and jumped 1274.15% in 2023.
• Over 5 years, Total Debt stood at $1.2 million in 2022, then jumped by 1274.15% to $16.8 million in 2023, then dropped by 20.96% to $13.3 million in 2024, then surged by 119.29% to $29.1 million in 2025, then declined by 13.91% to $25.0 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $25.0 million in Q2 2026, $24.9 million in Q1 2026, and $29.1 million in Q4 2025.